article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

article thumbnail

Unlocking disease treatment with large-scale research

pharmaphorum

A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped. However, the scale goes far beyond 100,000 genomes and instead is looking to recruit five million adult volunteers. Aims for the project.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Open science, genomics, and the quiet revolution in our approach to pharma

Drug Discovery World

Bioinformatics and genetic sequencing are starting to be placed front and centre of public research programmes as scientists from around the world recognise the substantial benefits of knowledge sharing and resource pooling when it comes to genetic science.

Genome 52
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). Emerging UK biotech firms like Mosaic Therapeutics, Enhanc3D Genomics, and Nucleome Therapeutics are using these genomic insights to innovate.”

Drugs 75